|Application ||IHC-P, WB, E|
|Calculated MW||57104 Da|
|Antigen Region||472-500 aa|
|Other Names||Prostacyclin synthase, Prostaglandin I2 synthase, PTGIS, CYP8, CYP8A1|
|Target/Specificity||This CYP8A1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 472-500 amino acids from the C-terminal region of human CYP8A1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CYP8A1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2).|
|Cellular Location||Endoplasmic reticulum membrane; Single-pass membrane protein|
|Tissue Location||Widely expressed; particularly abundant in ovary, heart, skeletal muscle, lung and prostate|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CYP8A1 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. However, this protein is considered a member of the cytochrome P450 superfamily on the basis of sequence similarity rather than functional similarity. This endoplasmic reticulum membrane protein catalyzes the conversion of prostglandin H2 to prostacyclin (prostaglandin I2), a potent vasodilator and inhibitor of platelet aggregation. An imbalance of prostacyclin and its physiological antagonist thromboxane A2 contribute to the development of myocardial infarction, stroke, and atherosclerosis.
Nelson,D.R., Pharmacogenetics 14 (1), 1-18 (2004)
If you have any additional inquiries please email technical services at email@example.com.